| Name | Title | Contact Details |
|---|---|---|
Andreas Busch |
Chief Innovation Officer | Profile |
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.
AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.
Vital Probes Inc is a Jermyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.